MSE
ACAD icon

MUFG Securities EMEA’s Acadia Pharmaceuticals ACAD Stock Holding History

MUFG Securities EMEA’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-32,500
Closed -$791K – 112
2014
Q1 		$791K Buy
+32,500
New +$822K 0.17% 62

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

MUFG Securities EMEA's ACAD Position: Q2 2014 in Review

MUFG Securities EMEA sold out of Acadia Pharmaceuticals (ACAD) in Q2 2014, closing a stake of 32,500 shares — an estimated $791K sold.

MUFG Securities EMEA first reported a position in ACAD in Q1 2014 and held it in 1 quarter. The position peaked at $791K in Q1 2014. 160 funds tracked by Wall St. Rank hold ACAD as of Q2 2014.

  • MUFG Securities EMEA reported no remaining Acadia Pharmaceuticals position as of Q2 2014 after selling out during the quarter.
  • MUFG Securities EMEA sold 32,500 Acadia Pharmaceuticals shares in Q2 2014, an estimated $791K.
  • MUFG Securities EMEA first reported a position in Acadia Pharmaceuticals in Q1 2014 and held it in 1 quarter.
  • MUFG Securities EMEA's Acadia Pharmaceuticals position peaked at $791K in Q1 2014.
  • 160 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2014.

Based on MUFG Securities EMEA's 13F filing for Q2 2014, filed 1 Aug 2014.